Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses oral spironolactone therapy for female patients with acne, hirsutism, or androgenic alopecia and reports no new clinical results.

This article discusses the role of estrogens in skin aging and reports no new findings; it highlights the potential of selective ER modulators to improve skin health without systemic side effects.

This review discusses the role of oestrogens in stimulating growth hormone secretion and influencing linear bone growth in children, and reports no new clinical results; the authors suggest that oestrogens play a key role in pubertal growth spurts for both genders.

In this study, 50 mg/day of DHEA supplementation in postmenopausal women did not significantly improve sexual function compared to a placebo over 26 weeks.

In this study, researchers used the FAERS database to identify rare adverse events potentially linked to spironolactone, finding new safety signals such as a possible association with male endometriosis, suggesting further research is needed to understand these findings better.

This review discusses the potential of lecithin organogels for improving topical drug delivery and presents no new experimental results; the authors highlight their stability and low skin irritancy as advantages.

This review discusses the causes and management of hirsutism, recommending low-dose oral contraceptives with flutamide over cyproterone-containing preparations, but reports no new clinical findings.

This study found that physician knowledge of thromboembolism risk associated with cyproterone acetate/ethinylestradiol was generally high, although it varied for complex or less common topics.

This study found that allopregnanolone has a bimodal effect on prolactin secretion in sheep, stimulating PRL mRNA expression but inhibiting hormone release under stress and pregnancy conditions.

This study conducted a large-scale comparison using FAERS data to assess the post-marketing safety profiles of spironolactone, eplerenone, and finerenone, finding unique adverse event patterns for each drug and highlighting the need for personalized safety monitoring and further investigation in other pharmacovigilance databases.

In this study, COC treatment led to greater improvements in sex hormone, endocrine factor, and metabolic levels among PCOS patients compared to those who did not receive the treatment.

In this study, prolonged systemic administration of 17β-estradiol in castrated male mice delayed wound healing by inhibiting re-epithelialization and reducing collagen accumulation, with estrogen receptor-α likely mediating this effect.

In this study, combining Kuntai capsules with nilestriol tablets for three months was found to reduce symptoms of perimenopausal syndrome and improve reproductive hormone levels more effectively than nilestriol alone; however, the benefits did not persist significantly beyond three months.

This study found that ursolic acid at 50 mg/kg improved biochemical, hormonal, and ovarian histopathological markers in a rat model of PCOS, suggesting its potential as a therapeutic option.

In this study, prolonged high-dose steroid treatment in rats caused several pathological changes, some of which regressed, particularly improvements in mammary gland tumors and pituitary-related symptoms, after stopping treatment.

This summary reviews the conflicting reports regarding 17β‐estradiol's effects on hair follicle growth, highlighting potential estrogen receptor-mediated impacts and calling for further research.

Spironolactone helps reduce hair growth in women with hirsutism but may cause menstrual irregularities.

This study found that hormonal IUD implantation was associated with an increased risk of acne vulgaris but a decreased risk of hirsutism, alopecia, and rosacea compared to nonhormonal copper IUDs.

This research review observed that topical hormone replacement therapy, particularly estradiol and estradiol-testosterone combinations, significantly increased Type I and III collagen synthesis in the skin of postmenopausal women, suggesting benefits against collagen loss-related skin aging effects such as reduced elasticity and increased dryness.

In this study, high-dose dutasteride significantly reduced several core symptoms of PMDD compared to placebo, supporting the role of neurosteroids in this condition.

This article reviews the effects of combined oral contraceptives on skin conditions and suggests prescribing guidelines for women with acne, as it reports no new clinical results.

Monitoring for adverse effects in clinical treatments is crucial.

This study found that oxybenzone is very stable under light exposure, contradicting previous findings of its oxidation to semiquinone after solar irradiation.

This abstract introduces TrichoFoam™, a new foaming vehicle for compounding pharmacies, designed to be a gentle, non-irritating option for alopecia treatment, acknowledging that current topical treatments are limited and oral products may cause adverse effects.

This article provides an overview of the indications, interactions, and various potential adverse reactions associated with several drugs, but it reports no specific new results.

This review discusses the hormonal influences on acne's development in women and the therapeutic potential of hormonal treatments, but it reports no new clinical results.

In this randomized study of male contraceptive regimens, adding finasteride did not significantly enhance spermatogenesis suppression compared to the control group.

Spironolactone can cause side effects like high potassium levels and breast enlargement, and patients need careful monitoring.

This article reviews how to identify and manage androgenic alopecia caused by hormonal contraceptives but reports no new clinical findings.